Literature DB >> 18080093

Mycophenolate mofetil therapy in uveitis: analysis of eight cases in a tertiary ophthalmic care centre in India.

Vishal M Rathore1, Rupesh Agrawal, S P Chaudhary, Jyotirmay Biswas.   

Abstract

Mycophenolate mofetil (MMF) is a relatively new immunomodulatory agent. The experience of MMF in inflammatory eye diseases is limited to a few case series. We report our experience of MMF in eight patients with uveitis. Control of inflammation was achieved in all patients. No patient had adverse side effects. Our study indicates that MMF is a safe and effective immunomodulatory agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18080093     DOI: 10.1007/s10792-007-9179-x

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  30 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

Review 2.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

3.  Rescue therapy with mycophenolate mofetil in refractory uveitis.

Authors:  D J Kilmartin; J V Forrester; A D Dick
Journal:  Lancet       Date:  1998-07-04       Impact factor: 79.321

4.  Multifocal choroiditis and panuveitis: immunomodulatory therapy.

Authors:  Shawkat Shafik Michel; Anthony Ekong; Stefanos Baltatzis; C Stephen Foster
Journal:  Ophthalmology       Date:  2002-02       Impact factor: 12.079

5.  Mycophenolate mofetil (MMF) versus azathioprine (AZA) in pancreas transplantation: a single-center experience.

Authors:  P Rigotti; R Cadrobbi; N Baldan; G Sarzo; P Parise; L Furian; F Marchini; E Ancona
Journal:  Clin Nephrol       Date:  2000-04       Impact factor: 0.975

Review 6.  Treatment of systemic lupus erythematosus with mycophenolate mofetil.

Authors:  D Adu; J Cross; D R Jayne
Journal:  Lupus       Date:  2001       Impact factor: 2.911

7.  [Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis].

Authors:  M Zierhut; N Stübiger; W Aboalchamat; H Landenberger; A A Bialasiewicz; K Engelmann
Journal:  Ophthalmologe       Date:  2001-07       Impact factor: 1.059

8.  Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.

Authors:  Robert P Baughman; Elyse E Lower; Deborah A Bradley; Lawrence A Raymond; Adam Kaufman
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

9.  Therapy of rheumatoid arthritis with mycophenolate mofetil.

Authors:  R Goldblum
Journal:  Clin Exp Rheumatol       Date:  1993 Mar-Apr       Impact factor: 4.473

10.  [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis].

Authors:  K Greiner; M Varikkara; C Santiago; J V Forrester
Journal:  Ophthalmologe       Date:  2002-09       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.